MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$223K
Free Cash flow
-$6,327K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities and sal...
Stock-based compensation
Accounts payable
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Payroll related expenses
Consulting and professional fees
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
30
14
10
16
Cost of revenue
50
42
42
41
Payroll related expenses
5,487
4,598
4,493
4,360
Consulting and professional fees
1,641
1,923
1,555
1,514
Stock-based compensation expense
823
835
1,019
1,254
Equipment, lab supplies, and facility expenses
354
313
302
422
Clinical studies and outside processing
154
122
468
394
Depreciation and amortization
162
164
215
214
Other segment items
1,363
1,377
870
797
Loss from operations
-10,004
-9,360
-8,954
-8,980
Interest expense
2
2
1
2
Other income, net
867
963
1,074
1,168
Net loss
-9,139
-8,399
-7,881
-7,814
Depreciation and amortization
191
193
244
243
Stock-based compensation
823
835
1,019
1,254
Non-cash lease expense
58
67
66
125
Non-cash investment income, net
-224
-6
-242
-33
Other
2
16
0
0
Accounts receivable
-1
-1
-2
-3
Other receivables
0
-
0
0
Prepaid expenses and other assets
-449
1,270
467
488
Accounts payable
811
-70
-94
52
Accrued and other current liabilities
287
-116
753
16
Deferred revenue
-14
-5
-4
99
Net cash used in operating activities
-6,311
-8,774
-6,120
-6,477
Purchases of marketable securities
10,664
1,007
7,780
7,969
Proceeds from maturities and sales of marketable securities
17,110
10,000
14,000
13,250
Purchases of property and equipment
16
8
330
112
Purchase of intangible assets
36
-
0
0
Net cash provided by (used in) investing activities
6,394
8,985
5,890
5,169
Proceeds from public offering of common stock, net of issuance costs
0
0
0
0
Proceeds from exercise of stock options
41
22
66
393
Proceeds from employee stock purchase plan
99
-
28
0
Finance lease principal payments
0
2
1
20
Net cash provided by financing activities
140
20
93
373
Net increase in cash and cash equivalents
223
231
-137
-935
Cash and cash equivalents at beginning of period
4,175
3,944
4,081
4,043
Cash and cash equivalents at end of period
4,398
4,175
3,944
4,081
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
and sales of...
$17,110K
(-47.49%↓ Y/Y)
Proceeds from employee
stock purchase plan
$99K
(32.00%↑ Y/Y)
Proceeds from exercise of
stock options
$41K
(-14.58%↓ Y/Y)
Net cash provided by
(used in) investing...
$6,394K
(116.16%↑ Y/Y)
Net cash provided by
financing activities
$140K
(-99.74%↓ Y/Y)
Canceled cashflow
$10,716K
Net increase in cash
and cash...
$223K
(-77.08%↓ Y/Y)
Canceled cashflow
$6,311K
Purchases of marketable
securities
$10,664K
(-85.16%↓ Y/Y)
Purchase of intangible
assets
$36K
Purchases of property and
equipment
$16K
(-94.37%↓ Y/Y)
Stock-based compensation
$823K
(-70.99%↓ Y/Y)
Accounts payable
$811K
(183.87%↑ Y/Y)
Prepaid expenses and
other assets
-$449K
(25.54%↑ Y/Y)
Accrued and other
current liabilities
$287K
(429.89%↑ Y/Y)
Non-cash investment
income, net
-$224K
(-474.36%↓ Y/Y)
Depreciation and
amortization
$191K
(-57.84%↓ Y/Y)
Non-cash lease expense
$58K
(-80.73%↓ Y/Y)
Accounts receivable
-$1K
(94.12%↑ Y/Y)
Net cash used in
operating activities
-$6,311K
(51.55%↑ Y/Y)
Canceled cashflow
$2,844K
Other income, net
$867K
(-63.00%↓ Y/Y)
Net loss
-$9,139K
(43.70%↑ Y/Y)
Canceled cashflow
$867K
Deferred revenue
-$14K
(-366.67%↓ Y/Y)
Other
$2K
(-60.00%↓ Y/Y)
Revenue
$30K
(-45.45%↓ Y/Y)
Loss from operations
-$10,004K
(46.13%↑ Y/Y)
Canceled cashflow
$30K
Interest expense
$2K
(-66.67%↓ Y/Y)
Payroll related
expenses
$5,487K
(-30.47%↓ Y/Y)
Consulting and
professional fees
$1,641K
(-57.65%↓ Y/Y)
Other segment items
$1,363K
(-32.69%↓ Y/Y)
Stock-based compensation
expense
$823K
(-70.99%↓ Y/Y)
Equipment, lab supplies,
and facility...
$354K
(-55.92%↓ Y/Y)
Depreciation and
amortization
$162K
(-58.99%↓ Y/Y)
Clinical studies and
outside processing
$154K
(-78.52%↓ Y/Y)
Cost of revenue
$50K
(-38.27%↓ Y/Y)
Buy us a coffee
SERA PROGNOSTICS, INC. (SERA)
SERA PROGNOSTICS, INC. (SERA)